<code id='85ACEE5D98'></code><style id='85ACEE5D98'></style>
    • <acronym id='85ACEE5D98'></acronym>
      <center id='85ACEE5D98'><center id='85ACEE5D98'><tfoot id='85ACEE5D98'></tfoot></center><abbr id='85ACEE5D98'><dir id='85ACEE5D98'><tfoot id='85ACEE5D98'></tfoot><noframes id='85ACEE5D98'>

    • <optgroup id='85ACEE5D98'><strike id='85ACEE5D98'><sup id='85ACEE5D98'></sup></strike><code id='85ACEE5D98'></code></optgroup>
        1. <b id='85ACEE5D98'><label id='85ACEE5D98'><select id='85ACEE5D98'><dt id='85ACEE5D98'><span id='85ACEE5D98'></span></dt></select></label></b><u id='85ACEE5D98'></u>
          <i id='85ACEE5D98'><strike id='85ACEE5D98'><tt id='85ACEE5D98'><pre id='85ACEE5D98'></pre></tt></strike></i>

          Home / knowledge / entertainment

          entertainment


          entertainment

          author:knowledge    Page View:457
          David L. Ryan/Boston Globe

          A team of high-powered scientists and billionaire investors said Friday that they’re launching a biomedical institute in Cambridge’s Kendall Square with $500 million in private funding with the aim of shortening the path from research breakthroughs to life-saving medicines.

          The institute, called Arena BioWorks, will put drug discovery and company creation under one roof, upending the traditional model where academic research and venture-backed drug development are separate.

          advertisement

          Backed by deep-pocketed investors including Steve Pagliuca, the former co-chair of Bain Capital and Celtics co-owner, and high-tech mogul Michael Dell, Arena has already lured top scientists from academic labs with lucrative compensation packages, but so far has publicly named only a few.

          Get unlimited access to award-winning journalism and exclusive events.

          Subscribe Log In